SCHEMBL2219351

SCHEMBL2219351

Cc1ccc(S(=O)(=O)N2C3CCCC2CC(=O)C3)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.64
MCOLN3 Q8TDD5 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 1/20 0.49
PKM P14618 3/20 0.47
MMP2 P08253 2/20 0.47
POLB P06746 1/20 0.47
HTT P42858 1/20 0.47
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
MAPK1 P28482 1/20 0.46
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
ANPEP P15144 1/20 0.44
KDM2B Q8NHM5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8251036 0.84 PSEN1 (0.62) ACHEALDH1A1PKMMMP2PSEN1
SCHEMBL916558 0.84 PSEN1 (0.62) ACHEALDH1A1PKMMMP2PSEN1
SCHEMBL917161 0.84 ACHE (0.44) ACHEMCOLN3L3MBTL1ALDH1A1POLB
SCHEMBL2690876 0.81 ACHE (0.74) ACHEMCOLN3L3MBTL1ALDH1A1KDM4E
SCHEMBL13812162 0.81 ACHE (0.68) ACHEMCOLN3L3MBTL1ALDH1A1KDM4E
SCHEMBL13248930 0.78 ACHE (1.00) ACHEMCOLN3L3MBTL1ALDH1A1KDM4E
SCHEMBL19392468 0.78 ACHE (1.00) ACHEMCOLN3L3MBTL1ALDH1A1KDM4E
SCHEMBL13069242 0.78 ACHE (1.00) ACHEMCOLN3L3MBTL1ALDH1A1KDM4E
SCHEMBL537069 0.78 ACHE (0.69) ACHEMCOLN3L3MBTL1ALDH1A1KDM4E
SCHEMBL916742 0.77 HSD11B1 (0.43) ACHEMMP2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178119-A1 Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. (US) 2011-07-21 US claimed
EP-1915371-A2 BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2008-04-30 EP claimed
WO-2007024651-A2 BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-03-01 WO claimed
US-20230295322-A1 BINDING MOLECULES AGAINST BCMA AND USES THEREOF NOVARTIS AG (CH) 2023-09-21 US disclosed
US-20110178119-A1 Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. (US) 2011-07-21 US disclosed
EP-1915371-A2 BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2008-04-30 EP disclosed
WO-2007024651-A2 BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295322-A1 BINDING MOLECULES AGAINST BCMA AND USES THEREOF EPCAM, CD40, BCR ACHE 2795/4885MCOLN3 4766/4885L3MBTL1 665/4885
US-20110178119-A1 Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 ACHE 17/4885MCOLN3 4483/4885L3MBTL1 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.